Blue Earth Drug Patent Portfolio
Blue Earth owns 2 orange book drugs protected by 11 US patents Given below is the list of Blue Earth's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11980674 | Imaging of metastatic or recurrent cancer | 23 Apr, 2042 | Active |
| US12036290 | Pharmaceutical formulations | 27 Nov, 2041 | Active |
| US11413360 | Dual mode radiotracer and—therapeutics | 22 Nov, 2038 | Active |
| US10124079 | Imaging of metastatic or recurrent cancer | 30 Dec, 2035 | Active |
| US10716868 | Imaging of metastatic or recurrent cancer | 30 Dec, 2035 | Active |
| US10933147 | Imaging of metastatic or recurrent cancer | 30 Dec, 2035 | Active |
| US10967077 | Imaging of metastatic or recurrent cancer | 30 Dec, 2035 | Active |
| US10010632 | Precursor compound of radioactive halogen-labeled organic compound | 28 Nov, 2026 | Active |
| US10953112 | Precursor compound of radioactive halogen-labeled organic compound | 28 Nov, 2026 | Active |
| US9387266 | Precursor compound of radioactive halogen-labeled organic compound | 28 Nov, 2026 | Active |
| US5808146 | Amino acid analogs for tumor imaging | 09 Nov, 2020 | Expired |
Latest Legal Activities on Blue Earth's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Blue Earth.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2024 | US10933147 |
|
Email Notification
Critical
| 28 Jun, 2024 | US10716868 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2024 | US10716868 |
|
Email Notification
Critical
| 28 Jun, 2024 | US10933147 |
|
Email Notification
Critical
| 28 Jun, 2024 | US10124079 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 28 Jun, 2024 | US10124079 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jun, 2024 | US10967077 |
|
Email Notification
Critical
| 20 Jun, 2024 | US10967077 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2024 | US10716868 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jan, 2024 | US9387266 |
| Post Issue Communication - Certificate of Correction | 10 Jul, 2023 | US11413360 |
|
Email Notification
Critical
| 23 Dec, 2022 | US11413360 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 23 Dec, 2022 | US11413360 |
|
Correspondence Address Change
Critical
| 19 Dec, 2022 | US11413360 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 16 Aug, 2022 | US11413360 |
Blue Earth's Family Patents
Blue Earth Drug List
Given below is the complete list of Blue Earth's drugs and the patents protecting them.
1. Axumin
Axumin is protected by 9 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11980674 | Imaging of metastatic or recurrent cancer |
23 Apr, 2042
(16 years from now)
| Active |
| US10124079 | Imaging of metastatic or recurrent cancer |
30 Dec, 2035
(10 years from now)
| Active |
| US10716868 | Imaging of metastatic or recurrent cancer |
30 Dec, 2035
(10 years from now)
| Active |
| US10933147 | Imaging of metastatic or recurrent cancer |
30 Dec, 2035
(10 years from now)
| Active |
| US10967077 | Imaging of metastatic or recurrent cancer |
30 Dec, 2035
(10 years from now)
| Active |
| US10010632 | Precursor compound of radioactive halogen-labeled organic compound |
28 Nov, 2026
(1 year, 6 months from now)
| Active |
| US10953112 | Precursor compound of radioactive halogen-labeled organic compound |
28 Nov, 2026
(1 year, 6 months from now)
| Active |
| US9387266 | Precursor compound of radioactive halogen-labeled organic compound |
28 Nov, 2026
(1 year, 6 months from now)
| Active |
| US5808146 | Amino acid analogs for tumor imaging |
09 Nov, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Axumin's drug page
2. Posluma
Posluma is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12036290 | Pharmaceutical formulations |
27 Nov, 2041
(16 years from now)
| Active |
| US11413360 | Dual mode radiotracer and—therapeutics |
22 Nov, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Posluma's drug page